To examine the influence of continuous exposure to TKIs on the PD-L1 expression in TKI-resistant NSCLC, H1975 cells which harbor the EGFR L858R/T790M double mutations were treated with Gefitinib or Erlotinib for 5 weeks. Here, CD274 is linked to non-small cell lung carcinoma.